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The latent membrane protein 1 (LMP1) of Epstein–Barr virus (EBV) is the only EBV protein which possesses the properties
of an oncogene. In studies initiated to evaluate the mechanisms involved in EBV-induced malignant transformation, the
extracellular response kinase (ERK) 1/2 were found to be activated 2 days after EBV infection of purified resting human B
cells. Transfection studies in Rat-1 fibroblasts, an established rodent cell line, showed that LMP1 mediates ERK 1/2
activation. Cotransfection experiments with a dominant negative ras mutant demonstrated that such MAPK activation occurs
via a ras-dependent pathway. Finally, cotransfection studies showed that ras activation is required for LMP-1-mediated
malignant transformation of Rat-1 cells. © 1998 Academic Press
INTRODUCTION
Epstein–Barr virus (EBV), a ubiquitous human herpes-
virus, is associated with a number of malignancies orig-
inating from lymphoid and epithelial cell types, including
endemic Burkitt’s lymphoma, several different T cell lym-
phomas, two subtypes of Hodgkin’s disease, undifferen-
tiated nasopharyngeal carcinoma and several other car-
cinomas (Fahraeus et al. 1988; Klein, 1989; Pallesen et
al., 1991; Su et al., 1991). The EBV genome also is found
with high frequency in the lymphomas and lymphoprolif-
erative diseases that occur in immunocompromised or-
gan transplant recipients and individuals with AIDS (Ho
et al. 1985; Karp and Broder, 1991).
The mechanisms responsible for oncogenic transfor-
mation of EBV-infected cells are incompletely under-
stood and remain a focus of intense study. Five of the 11
EBV latent genes are required for B cell transformation
by EBV (EBNA-1, EBNA-2, EBNA-3A, EBNA-3C, and
LMP1), and an additional gene, EBNA-LP, modulates B
cell immortalization, as shown by mutagenesis and re-
constitution approaches (Kaye et al., 1993; Hammer-
schmidt and Sugden, 1989; Mannick et al., 1991; Tomkin-
son et al., 1993). Several of the EBV latent genes
modulate cellular phenotype and growth characteristics
[reviewed in (Rickinson and Kieff, 1996)].
Latent membrane protein 1 (LMP1) is the only EBV
latent gene which conforms to the classical description
of an oncogene, since Rat-1 fibroblasts and NIH 3T3
cells exhibit malignant transformation after transfection
with LMP1. Such LMP1-expressing cells exhibit pheno-
typic changes, loss of contact inhibition, and the ability to
grow in reduced serum concentrations; furthermore, they
exhibit the property of anchorage-independent growth in
soft agar and the ability to induce tumors in nude mice
(Baichwal and Sugden, 1988; Wang et al., 1985). LMP1
also alters the growth characteristics of B cells, epithelial
cells and hematopoietic stem cells (Peng and Lundgren,
1992; Dawson et al., 1990; Fahraeus et al., 1990; Fairbairn
et al., 1993).
Protease digestion studies and other approaches in-
dicate that LMP1 is an integral membrane protein con-
sisting of a short 20-residue amino terminal sequence, 6
20 amino acid transmembrane segments separated by
short 8–10 amino acid reverse turns, and a long 200
amino acid carboxy terminal tail; both the amino and
carboxy termini are intracellular (Liebowitz et al., 1986).
All of the domains of the molecule appear to be required
for cellular transformation (Moorthy and Thorley-Lawson,
1993). The effects of LMP1 on cell growth characteristics
and its oncogenic properties are obviously dependent on
interactions of LMP1 with cellular proteins and intracel-
lular signaling pathways. Multiple such reactions have
been described. These include association of LMP1 with
the intermediate filament protein, vimentin; induction, by
LMP1, of increased cellular expression of CD11a/CD18,
CD23, CD39, CD40, CD44, CD54 vimentin, transferrin
receptor, MHC class II, and IL-10 (Birkenbach et al. 1989;
Rickinson and Kieff, 1996; Nakagomi et al., 1994). LMP1
also induces pRb hyperphosphorylation, expression of
cyclin D2, a calcium-calmodulin-dependent protein ki-
nase, and DNA synthesis (Mosialos et al., 1994; Arvani-
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takis et al., 1995; Peng and Lundgren, 1992). In addition,
LMP1 protects B cells from apoptosis via induction of
bcl-2 and the A20 anti-apoptosis protein, activates the
NFkB transcription factor, and interacts with tumor ne-
crosis factor (TNF) receptor-associated factor 1 and with
a novel cellular protein which is also related to TNF
receptor signaling proteins (Henderson et al. 1991; Mo-
sialos et al., 1995; Gregory et al. 1991; Laherty et al.,
1992). Finally, we have recently reported that LMP1 trans-
activates expression of transcriptionally active p53 via
NFkB activation (Chen and Cooper, 1996).
The relationship of these multiple interactions with
cellular proteins and signaling events to growth immor-
talization and transformation is not clear. The present
studies were initiated to determine whether EBV acti-
vates the ras/raf-1/MEK (mitogen-activated protein ki-
nase (MAPK) kinase or ERK kinase)/ERK 1/2 (extracellu-
lar response kinase) signal-transducing pathway. This
pathway mediates activation of c-fos, c-jun, and c-myc
and plays a crucial role in regulating cellular growth,
transformation, and differentiation in response to a vari-
ety of different extracellular stimuli (Pulverer et al., 1991;
Gille et al., 1992; Page`s et al., 1993; Cowley et al., 1994;
Troppmair et al., 1994). Aberrations in this pathway, or its
targets, are frequently tumorigenic. The studies pre-
sented here show that LMP1 activates the ras/raf-1/
MEK/ERK 1/2 pathway, and demonstrate that such acti-




Mycophenolic acid was obtained from Gibco/BRL.
Xanthine, hypoxanthine, myelin basic protein (MBP), 2-
aminoethylisothiouronium bromide (AET), protein A
beads, and PMA were purchased from Sigma. Ficoll–
Paque and Percoll were from Pharmacia.
B cell purification
Small, dense, resting B cells were purified from human
tonsils and characterized by flow cytofluorometry as pre-
viously described (Luxembourg and Cooper, 1994).
Briefly, after rosetting with AET-treated sheep erythro-
cytes, and centrifugation over Ficoll–Paque, small,
dense, resting B cells were collected from the 55–60%
interface of a discontinuous Percoll density gradient. The
cells, at the concentration of 1 3 106/ml, were main-
tained overnight at 37° in 5% CO2 in RPMI containing 10%
fetal calf serum before use. The cells employed in these
studies were consistently 95–98% CD191, 50–80%
IgM1, and 40–70% IgD1. They contained 0.5–3% CD31
cells, less than 1% CD141 cells, and less than 1%
CD561 cells.
EBV
B95-8 cells were stimulated for 8–14 days with 30
ng/ml of TPA, after which the virus was pelleted from the
culture supernatant and resuspended in RPMI contain-
ing 10% FCS.
MAPK (ERK) assay
MAPK activity was measured after 2 h of incubation of
the transfectant cells in serum-free media. The cells
were lysed in 2% NP-40 containing 50 mM Tris–HCl, pH
7.3, 5 mM EDTA, 5 mM sodium pyrophosphate, 5 mM
sodium fluoride, 50 mM sodium orthovanadate, 50 mg/ml
aprotinin, and 50 mg/ml leupeptin. Assays were carried
out either with the same number of cells (1.5 3 106 for
primary B cells) or the same amount of protein (80 mg for
the transfected cells). Lysates were precleared overnight
with protein A beads, and ERK 1/2 were immunoprecipi-
tated with a monoclonal antibody (mAb) which recog-
nizes ERK1 and ERK2 (Santa Cruz Biotechnology), to-
gether with protein A beads (Sigma). The ability of the
immunoprecipitated ERK 1/2 to phosphorylate MBP was
assessed in reaction mixtures containing 10 mg MBP in
30 mM Tris–HCl, pH 7.3, 20 mM MgCl2, 2 mM MnCl2, 10
mM ATP, and 10 mM of [g-32P]ATP (Amersham). Incuba-
tion was for 30 min at 30°, after which samples were
analyzed on 15% polyacrylamide gels. Bands were quan-
titated using a Phosphorimager (Molecular Dynamics).
Transfections
Rat-1 fibroblasts (kindly provided by J. Jackson), grown
in 1:1 DMEM/Hams F12, were stably transfected with 2
mg of either an LMP1 expression plasmid (pSV2gpt-
MTLM) (Wang et al., 1985), or the control plasmid
pSV2gpt (ATCC, Rockville, MD) using lipofectamine
(Gibco/BRL) according to the manufacturer’s instruc-
tions. Selection was started 3 days after transfection (25
mg/ml mycophenolic acid, 160 mg/ml xanthine, and 10
mg/ml hypoxanthine) (Wang et al., 1985). Single clones
were isolated, lysed, and evaluated for the presence of
LMP1 and ERK 1/2 proteins by the Western blotting
procedure (2.5 3 105 cells/sample) using the S12 and
ERK 1/2 mAbs to LMP1 (Mann et al., 1985) and MAPK
(Zymed Laboratories, Inc.), respectively. Reactivity was
detected with peroxidase-labeled anti-mouse immuno-
globulin G (Bio-Rad) using the ECL system (Amersham).
Rat-1 cells expressing LMP1 were transiently trans-
fected with 3 mg of a plasmid expressing the dominant
negative N17 ras mutant (pCMVN17), or the vector
(pCMV) using lipofectamine. Twenty hours after transfec-
tion, the cells were incubated for 3 h in serum-free
medium, lysed, and examined for ras protein expression
by the Western blotting procedure (2.5 3 105 cells/sam-
ple) using a mAb which recognizes both native and
transfected mutant ras (kindly provided by D. Cheresh).
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Rat-1 cells were also transfected with 3 mg of the N17
dominant negative ras mutant in the pZipneo expression
plasmid (pZipneoN17), together with the LMP1 expres-
sion plasmid (pSV2gptMTLM), with the pZipneo vector
together with pSV2gptMTLM, and with both vectors
alone using lipofectamine. Three days after transfection,
the cells were divided and selected in 15 mg/ml myco-
phenolic acid, 160 mg/ml xanthine, 10 mg/ml hypoxan-
thine, and 400 mg/ml G418. The selective media was
replaced every 3 days. The number of clones was deter-
mined 2 weeks after selection was initiated.
Finally, Rat-1 cells were transfected with 1 mg of
pZipNeoN17, together with 5 mg of PF4, a pBR322-
derived vector which contains the v-raf gene (ATCC), or
with the pZipNeoN17 expression vector together with 5
mg of vector (pBR322). Three days after transfection, the
cells were divided and selected in 400 mg/ml G418. The
selective media was replaced every 3 days. The number
of clones was determined 2 weeks after selection was
initiated.
Transformation assay
The assay was performed as previously described
(Moorthy and Thorley-Lawson, 1993). Two weeks after
initiating selection, the cells were fixed in methanol and
stained with 0.2% methylene blue and clones were
counted.
RESULTS
EBV infection of resting B cells activates ERK 1/2
MAPKs
In these studies, EBV was incubated with purified,
dense, resting (nonactivated) human B lymphocytes iso-
lated from human tonsils. Samples were taken at inter-
vals, lysed, and ERK 1/2 immunoprecipitates were as-
sessed for ability to phosphorylate MBP. No changes in
the level of MAPK activity were evident in uninfected
cells, or in infected cells for the first 24 h after EBV
addition (Fig. 1). However, ERK 1/2 activity increased 2
days after EBV infection and persisted for 4 days (Fig. 1)
and apparently, indefinitely, since MAPK was also com-
parably activated in immortal B-lymphoblastoid cell lines
established by in vitro infection with EBV (not shown).
The increase in MAPK activity over background levels
2–4 days after EBV infection of purified resting human B
cells ranged from 2.4- to 2.8-fold in a number of similar
studies. The phorbol ester, TPA, which induced a 10-fold
increase in MAPK activity, served as a positive control.
These data indicate that increased ERK 1/2 activity is
evident 2–4 days after EBV infection of resting B cells.
LMP1 mediates ERK 1/2 activation
Studies were carried out to determine whether LMP1
might be involved in ERK 1/2 activation, since this latent
gene product is first expressed approximately 2 days
after EBV addition, and reaches peak levels 4 to 5 days
after infection (Alfieri et al., 1991; Allday et al., 1989;
Sinclair et al., 1994). Furthermore, LMP1 expression in
primary B cells triggers DNA synthesis (Peng and Lund-
gren, 1992), a process which is suggestive of MAPK
involvement. In order to evaluate possible LMP1 involve-
ment in ERK 1/2 activation, Rat-1 fibroblasts were stably
transfected with an expression plasmid encoding LMP1
(pSV2gptMTLM) (Wang et al., 1985), or with a control
plasmid (pSV2gpt) (Mulligan and Berg, 1981). Western
blotting studies showed the presence of LMP1 only in
the transfected cells, and comparable ERK 1/2 levels in
LMP1 and vector-transfected cells (Fig. 2A), a result
replicated in three identical studies. ERK 1/2 activity was,
however, considerably greater in the LMP1 transfectants
(3.8- to 5.0-fold in various experiments), than in the vec-
tor-transfected cells (Fig. 2B). Thus, LMP1 expression in
Rat-1 fibroblasts is accompanied by ERK 1/2 activation.
FIG. 1. EBV infection of purified resting human B cells increases
MAPK activity in a time-dependent manner. Samples were taken at the
indicated times after infection, and ERK 1/2 immunoprecipitates were
assessed for ability to phosphorylate MBP.
FIG. 2. LMP1-mediated ERK 1/2 activation in transfected Rat-1 fibro-
blasts. (A) Cellular extracts from Rat-1 cells stably transfected with the
LMP1 expression plasmid (pSV2gptMTLM), or with vector alone
(pSV2gpt), were lysed and assessed for LMP1 protein by the Western
blotting procedure using the S12 mAb to LMP1. The LMP1 and vector-
transfected Rat-1 cells were also evaluated for the presence of MAPK
protein using a mAb to ERK 1/2. (B) Samples from LMP1 and vector-
transfected Rat-1 cells were lysed, and ERK 1/2 immunoprecipitates
were assessed for MAPK activity by ability to phosphorylate MBP.
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LMP1-mediated ERK 1/2 activation is ras dependent
Upstream sequentially acting members of the pathway
leading to ERK 1/2 activation include p21 ras, raf-1, and
MEK. In order to determine whether ras was involved in
the LMP1-triggered pathway leading to ERK 1/2 activa-
tion, the LMP1 stably transfected Rat-1 cells were tran-
siently transfected with a dominant negative ras mutant
(N17, with the serine at position 17 mutated to aspara-
gine) (Feig and Cooper, 1988). Western blotting studies,
with a mAb which recognizes native and mutant ras,
showed a marked increase in ras levels in the ras N17
transfected cells (Fig. 3A). However, ERK 1/2 activity was
significantly decreased in the LMP1 expressing cells
transfected with dominant negative ras (Fig. 3B), to levels
which were comparable to those observed in Rat-1 cells
transfected with the pSV2gpt vector (compare Fig. 2B). In
three independent experiments, 57, 72, and 100% inhibi-
tion of ERK 1/2 activity was observed; these values cor-
respond to the respective transfection efficiencies, as
determined by X-gal staining. Thus, increased ERK 1/2
activity in Rat-1 fibroblasts stably transfected with LMP1
depends on the presence of functionally active ras.
Transformation of rat-1 cells by LMP1 is ras
dependent
LMP1 expressing Rat-1 cells exhibit phenotypic
changes, loss of contact inhibition, and anchorage-inde-
pendent growth in agar, and they induce tumors in
nude mice, as noted earlier. Studies were carried out to
determine whether LMP1-mediated transformation of
Rat-1 cells in vitro is ras dependent. In these studies,
Rat-1 cells were cotransfected with the N17 dominant
negative ras mutant in a pZipNeo expression plasmid
(pZipNeoN17) together with the LMP1 expression plas-
mid described earlier (pSV2gptMTLM); with the pZipNeo
vector together with the LMP1 expression plasmid, or
with both vectors alone (pZipNeo and pSV2gpt). Due to
growth as piled-up clones, the clumped transformed
cells have a higher cell density and stain much more
darkly with methylene blue than the nontransformed
clones, which exhibit contact inhibition; thus, trans-
formed foci are readily distinguishable from nontrans-
formed clones by visual inspection (Moorthy and Thor-
ley-Lawson, 1993). A representative example of one of
three identical experiments is shown in Fig. 4. No trans-
formed clones were evident among the numerous clones
produced by the Rat-1 cells transfected with both vectors
(Fig. 4A). In contrast, transformed clones were readily
visualized in the Rat-1 cells transfected with LMP1 plus
pZipNeo (Fig. 4B). In this experiment, 16% of the clones
were transformed. In the other two experiments, 6.5 and
6.7% of the clones were transformed after transfection
with LMP1 plus the N17 vector (not shown). No cells
were present in the samples cotransfected with the ras
N17 mutant together with LMP1 (Fig. 4C). The effects of
LMP1 and the N17 ras mutant on cell growth were
confirmed in another experiment in which the numbers of
clones were determined (Fig. 4D). As is evident, the N17
dominant negative ras mutant interfered with cell growth,
regardless of the presence or absence of LMP1. These
effects of the dominant negative ras mutant were antic-
ipated, since ras is essential for cell division (Barbacid,
1987; Mulcahy et al., 1985) and overexpressed mutant
ras inhibits cell growth (Stacey et al., 1991; Feig and
Cooper, 1988). In order to rule out nonspecific toxicity or
other effects unrelated to the ras/raf-1 MEK/ERK 1/2
signaling pathway as responsible for the observed
growth inhibition, Rat-1 cells were cotransfected with the
N17 dominant negative ras mutant, together with an
expression vector containing the v-raf gene, a down-
stream effector in the pathway. Expression of constitu-
tively active v-raf reversed the growth inhibition pro-
duced by the dominant negative ras mutant (Fig. 4D).
The few drug-resistant clones in the pBR322 and
pZipNeoN17 control probably represent clones with lev-
els of expression of the N17 ras mutant which are not
high enough to prevent cell growth, analogous to a
published report (Feig and Cooper, 1988). These data
cumulatively indicate that the LMP1-mediated effects
leading to transformation of Rat-1 fibroblasts are ras
dependent.
DISCUSSION
Although the LMP1 oncogene interacts with a number
of cellular signaling proteins, as earlier reviewed, it has
not been determined whether these include the ras/raf-
1/MEK/ERK 1/2 signal-transducing pathway. This is rel-
evant because of the crucial role of this pathway in
regulating cellular growth and differentiation, as consid-
ered above.
The present studies show that EBV infection of resting
human B cells activates ERK 1/2. Transfection ap-
proaches in Rat-1 fibroblasts revealed that LMP1 pro-
duces a 3.8- to 5.0-fold increase in ERK 1/2 activity, and
that such LMP1-mediated MAPK activation was abro-
FIG. 3. LMP-mediated MAPK activation is ras dependent. (A) Rat-1
cells stably transfected with LMP1 were transiently transfected with a
dominant negative ras mutant in a CMV vector (pCMVN17), or with a
control vector (pCMV). Twenty hours later, the cells were incubated in
serum-free media for 3 h, lysed, and examined for ras protein expres-
sion by the Western blotting procedure using a mAb to ERK 1/2. (B) ERK
1/2 immunoprecipitates were evaluated for MAPK activity by ability to
phosphorylate MBP.
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gated in cells coexpressing a dominant negative ras
mutant. These data indicate that functionally active ras,
rather than other signaling mechanisms (Kolch et al.,
1993; Johnson et al., 1996), is required for LMP1-medi-
ated ERK 1/2 activation.
Unfortunately, it was not possible to carry out similar
transfection studies in B cells, due to the extremely low
transfection efficiencies which these cells exhibit. How-
ever, lovastatin, an inhibitor of protein isoprenylation, and
thus of ras activation (Repko and Maltese, 1989), inhib-
ited EBV-induced ERK 1/2 activation and proliferation in B
cells 4 days after infection in a dose-dependent manner,
with 50% inhibition occurring at a concentration of 85 mM
(not shown). Although lovastatin is not a specific ras
inhibitor and has other inhibitory effects in cells, these
findings are consistent with a critical role of the ras
pathway in EBV-induced ERK 1/2 activation and prolifer-
ation of B cells.
LMP1 induced transformation of Rat-1 fibroblasts, in
confirmation of previously published results (Wang et al.,
1985). The role of the ras pathway in such LMP1-medi-
ated transformation was also investigated via the use of
transfection approaches. The dominant negative N17 ras
mutant inhibited the growth of Rat-1 fibroblasts, regard-
less of the presence or absence of LMP1. This negative
effect of the N17 mutant plasmid on Rat-1 cell growth
was not due to general cell toxicity or to other effects
unrelated to the ras/raf-1/MEK/ERK 1/2 signaling path-
way, since cotransfection of the N17 dominant negative
ras mutant together with constitutively active viral raf-1,
the immediate downstream target of ras, restored cell
growth. These findings indicate, therefore, that the ef-
fects of the N17 ras mutant in Rat-1 cells occur via a raf-1
signaling pathway. In this context, the susceptibility of
LMP1-mediated Rat-1 transformation to inhibition by
dominant negative ras and the inability of LMP1 to coun-
teract the effects of the ras mutant indicates that the
LMP1 effects proceed via ras and, therefore, that ras
activation is essential for LMP1-mediated transformation
of Rat-1 cells. These findings add the ras/raf-1/MEK/ERK
1/2 pathway to other growth-regulating signaling path-
ways which have been shown to be triggered by LMP1.
These include activation of NFkB (Laherty et al., 1992;
Hammarskjo¨ld and Simurda, 1992; Huen et al., 1995),
triggering of a signaling pathway leading to induction of
cyclin D2 (Arvanitakis et al., 1995), and LMP1 interactions
FIG. 4. Transformation of Rat-1 cells is ras dependent. (A) Rat-1 cells were cotransfected with the LMP1 vector (pSV2gpt) plus the N17 vector
(pZipNeo); (B) with the LMP1 expression plasmid plus the N17 vector (pZipNeo); or (C) with an LMP1 expression plasmid (pSV2gptMTLM) together
with a dominant negative ras mutant (pZipNeoN17). (D) Rat-1 cells were cotransfected with the LMP1 expression plasmid plus the N17 vector
(pZipNeo), with the LMP1 vector (pSV2gpt) plus the N17 ras mutant (pZipNeoN17), or with the LMP1 expression plasmid (pSV2gptMTLM) plus the N17
ras mutant (pZipNeoN17). In a separate experiment, Rat-1 cells were cotransfected with the v-raf vector (pBR322) plus the N17 ras mutant
(pZipNeoN17) or with the v-raf expression plasmid (PF4) plus the N17 ras mutant (pZipNeoN17). Three days later, the cells were placed in selective
media and assessed 2 weeks later for the characteristics of cell growth and the number of clones.
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with members of the TNF receptor signaling pathway
(Mosialos et al., 1995). Some interactions between these
pathways have been described, and others undoubtedly
exist. Further study is needed to determine the functional
significance of these multiple signaling pathways in me-
diating the various functions of the LMP1 molecule.
The ras/raf-1/MEK/ERK 1/2 pathway is also likely to be
required for the transformation of B cells, although this
point was not formally demonstrated in the present stud-
ies for technical reasons. If so, the ras/raf-1/MEK/ERK 1/2
pathway could provide a potential target for therapeutic
intervention in immunocompromised patients suffering
from EBV-induced B cell lymphoproliferative disorders
and lymphomas. In this regard, farnesyl transferase in-
hibitors may find utility in the treatment of these disor-
ders.
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